Lynparza (olaparib), a product of Fortune 500 pharmaceutical company Merck and Fortune 500 Europe company AstraZeneca, showed significant improvements in overall survival in people with BRCA-mutated (gBRCAm), high-risk, HER2-negative early breast cancer, in a 2024 clinical trial. the data suggest.
Jaime Grajales Benjumea—Getty Images
